Search all medical codes

Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) and influenza virus types a and b, multiplex amplified probe technique

CPT4 code

Name of the Procedure:

Infectious agent detection by nucleic acid (DNA or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus Disease [COVID-19]) and Influenza virus types A and B, Multiplex Amplified Probe Technique


This is a diagnostic test that detects the genetic material of SARS-CoV-2 (the virus that causes COVID-19) and Influenza viruses A and B from a single sample using a technique that amplifies and identifies specific viral nucleic acids.


This test is used to diagnose COVID-19 and Influenza A and B. The goal is to identify the presence of these viruses accurately, which helps in timely and appropriate medical intervention.


  • Symptoms such as fever, cough, fatigue, body aches, sore throat, headache, loss of taste or smell, shortness of breath, or other respiratory symptoms.
  • Close contact with someone who has tested positive for COVID-19 or Influenza.
  • Requirement for diagnosis during peak flu seasons or in situations of viral outbreaks.


  • No special preparation is needed, though some facilities may recommend avoiding eating or drinking for a few hours before sample collection.
  • The patient should inform healthcare providers of any nasal sprays or medications currently being used.

Procedure Description

  1. A healthcare professional will collect a sample, usually a nasal or throat swab.
  2. The sample is then processed in a laboratory where the nucleic acids (DNA or RNA) of the viruses are extracted.
  3. Using the multiplex amplified probe technique, specific segments of viral genetic material are amplified and detected.
  4. Results are typically available within a few hours to a few days, depending on the laboratory's capacity.


The actual sample collection takes only a few minutes. Processing and analysis in the lab can take a few hours to a few days.


The sample collection can be done at various settings including hospitals, outpatient clinics, drive-through testing sites, and in some cases, at home test kits are available. The analysis is conducted in a specialized laboratory.


Sample collection is typically done by nurses, medical assistants, or trained healthcare workers. Laboratory professionals such as medical technologists or molecular biologists perform the analysis.

Risks and Complications

  • Mild discomfort or irritation at the site of sample collection (e.g., nasal or throat swab).
  • Rarely, nosebleeds or gagging may occur.


  • Accurate identification of SARS-CoV-2 and Influenza A and B infections.
  • Rapid results facilitate early and appropriate medical intervention and isolation measures.


  • There is no recovery period required as the procedure is non-invasive.
  • Patients can resume normal activities immediately after the sample is collected.
  • Follow-up might be necessary if the test is positive to ensure appropriate care and treatment.


  • Other diagnostic methods include rapid antigen tests for COVID-19 and Influenza, which are faster but generally less accurate.
  • Serological tests to detect antibodies can indicate past infections but are not useful for early detection.

Patient Experience

  • During the swab collection, the patient might feel brief discomfort or tingling.
  • Post-procedure, there might be minor irritation where the swab was taken.
  • Pain management is generally not necessary as the procedure is quick and minimally invasive.

Medical Policies and Guidelines for Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) and influenza virus types a and b, multiplex amplified probe technique

Related policies from health plans

Similar Codes